HCN4 and heart failure: In the genetic model of ivabradine, the competing risk analysis accounting for atrial fibrillation showed that the HCN4 heart rate-reducing variant protected against heart failure (HR = 0.90, 95% CI: 0.83–0.98, P = 0.013).